Neuren Pharmaceuticals Limited (NEU.AX)
AUD 10.98
(-1.35%)
AUD 10.98
(-1.35%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 32.69 Million AUD | 102.49% |
| 2022 | 16.13 Million AUD | 41.3% |
| 2021 | 11.42 Million AUD | 19.98% |
| 2020 | 9.52 Million AUD | -17.7% |
| 2019 | 11.56 Million AUD | 129.78% |
| 2018 | 5.03 Million AUD | -24.03% |
| 2017 | 6.62 Million AUD | -56.08% |
| 2016 | 15.08 Million AUD | -12.09% |
| 2015 | 17.16 Million AUD | 35.64% |
| 2014 | 12.65 Million AUD | 2.37% |
| 2013 | 12.36 Million AUD | 30.41% |
| 2012 | 9.47 Million AUD | 14.86% |
| 2011 | 8.25 Million AUD | -12.65% |
| 2010 | 9.44 Million AUD | 86.84% |
| 2009 | 5.05 Million AUD | -58.53% |
| 2008 | 12.19 Million AUD | -14.24% |
| 2007 | 14.21 Million AUD | 15.11% |
| 2006 | 12.35 Million AUD | 5.39% |
| 2005 | 11.71 Million AUD | 39.2% |
| 2004 | 8.41 Million AUD | 1539.22% |
| 2003 | 513.6 Thousand AUD | -2.17% |
| 2002 | 524.99 Thousand AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 20.26 Million AUD | 0.0% |
| 2023 Q2 | 14.77 Million AUD | 0.0% |
| 2023 FY | 32.68 Million AUD | 102.49% |
| 2023 Q4 | 17.9 Million AUD | 0.0% |
| 2022 Q4 | 8.8 Million AUD | 0.0% |
| 2022 FY | 16.13 Million AUD | 41.3% |
| 2022 Q2 | 7.33 Million AUD | 0.0% |
| 2021 Q2 | 8.19 Million AUD | 0.0% |
| 2021 FY | 11.42 Million AUD | 19.98% |
| 2021 Q4 | 3.22 Million AUD | 0.0% |
| 2020 FY | 9.52 Million AUD | -17.7% |
| 2020 Q2 | 5.31 Million AUD | 0.0% |
| 2020 Q4 | 4.2 Million AUD | 0.0% |
| 2019 FY | 11.56 Million AUD | 129.78% |
| 2019 Q2 | 7.9 Million AUD | 0.0% |
| 2019 Q4 | 3.66 Million AUD | 0.0% |
| 2018 Q4 | 3.53 Million AUD | 0.0% |
| 2018 FY | 5.03 Million AUD | -24.03% |
| 2018 Q2 | 1.49 Million AUD | 0.0% |
| 2017 Q2 | 1.49 Million AUD | 0.0% |
| 2017 Q4 | 9.23 Million AUD | 0.0% |
| 2017 FY | 6.62 Million AUD | -56.08% |
| 2016 Q2 | 1.87 Million AUD | 0.0% |
| 2016 FY | 15.08 Million AUD | -12.09% |
| 2016 Q4 | 154 Thousand AUD | 0.0% |
| 2015 Q4 | 982 Thousand AUD | 0.0% |
| 2015 FY | 17.16 Million AUD | 35.64% |
| 2015 Q2 | 1.04 Million AUD | 0.0% |
| 2014 Q2 | 2.02 Million AUD | 0.0% |
| 2014 Q4 | 228 Thousand AUD | 0.0% |
| 2014 FY | 12.65 Million AUD | 2.37% |
| 2013 Q4 | 4.8 Million AUD | 7700.47% |
| 2013 FY | 12.36 Million AUD | 30.41% |
| 2013 Q3 | 61.58 Thousand AUD | -96.91% |
| 2013 Q2 | 1.99 Million AUD | 3132.88% |
| 2013 Q1 | 61.58 Thousand AUD | 0.0% |
| 2012 Q2 | 1.63 Million AUD | 0.0% |
| 2012 Q3 | 1.63 Million AUD | 0.0% |
| 2012 FY | 9.47 Million AUD | 14.86% |
| 2012 Q4 | 61.58 Thousand AUD | -96.23% |
| 2012 Q1 | 1.63 Million AUD | 0.0% |
| 2011 Q3 | 36.51 Thousand AUD | 0.0% |
| 2011 Q1 | 36.51 Thousand AUD | 0.0% |
| 2011 Q2 | 36.51 Thousand AUD | 0.0% |
| 2011 FY | 8.25 Million AUD | -12.65% |
| 2011 Q4 | 1.63 Million AUD | 4369.12% |
| 2010 Q3 | 76.11 Thousand AUD | 0.0% |
| 2010 Q1 | 76.11 Thousand AUD | 0.0% |
| 2010 Q4 | 36.51 Thousand AUD | -52.03% |
| 2010 FY | 9.44 Million AUD | 86.84% |
| 2010 Q2 | 76.11 Thousand AUD | 0.0% |
| 2009 Q2 | 104.21 Thousand AUD | 0.0% |
| 2009 Q4 | 76.11 Thousand AUD | -26.97% |
| 2009 Q1 | 104.21 Thousand AUD | 0.0% |
| 2009 Q3 | 104.21 Thousand AUD | 0.0% |
| 2009 FY | 5.05 Million AUD | -58.53% |
| 2008 Q2 | 154.95 Thousand AUD | 0.0% |
| 2008 Q3 | 154.95 Thousand AUD | 0.0% |
| 2008 Q4 | 104.21 Thousand AUD | -32.74% |
| 2008 FY | 12.19 Million AUD | -14.24% |
| 2008 Q1 | 154.95 Thousand AUD | 0.0% |
| 2007 Q3 | 123.3 Thousand AUD | 0.0% |
| 2007 Q1 | 123.3 Thousand AUD | 0.0% |
| 2007 FY | 14.21 Million AUD | 15.11% |
| 2007 Q4 | 154.95 Thousand AUD | 25.67% |
| 2007 Q2 | 123.3 Thousand AUD | 0.0% |
| 2006 Q4 | 123.3 Thousand AUD | -4.95% |
| 2006 Q3 | 129.72 Thousand AUD | 0.0% |
| 2006 FY | 12.35 Million AUD | 5.39% |
| 2006 Q1 | 129.72 Thousand AUD | 0.0% |
| 2006 Q2 | 129.72 Thousand AUD | 0.0% |
| 2005 Q1 | 2.72 Million AUD | 0.0% |
| 2005 Q2 | 2.72 Million AUD | 0.0% |
| 2005 Q3 | 2.72 Million AUD | 0.0% |
| 2005 Q4 | 129.72 Thousand AUD | -95.24% |
| 2005 FY | 11.71 Million AUD | 39.2% |
| 2004 Q2 | 29.07 Thousand AUD | 0.0% |
| 2004 FY | 8.41 Million AUD | 1539.22% |
| 2004 Q4 | 2.72 Million AUD | 9271.88% |
| 2004 Q1 | 29.07 Thousand AUD | 0.0% |
| 2004 Q3 | 29.07 Thousand AUD | 0.0% |
| 2003 Q1 | 128.4 Thousand AUD | 0.0% |
| 2003 Q3 | 128.4 Thousand AUD | 0.0% |
| 2003 FY | 513.6 Thousand AUD | -2.17% |
| 2003 Q4 | 29.07 Thousand AUD | -77.36% |
| 2003 Q2 | 128.4 Thousand AUD | 0.0% |
| 2002 FY | 524.99 Thousand AUD | 0.0% |
| 2002 Q1 | 131.24 Thousand AUD | 0.0% |
| 2002 Q2 | 131.24 Thousand AUD | 0.0% |
| 2002 Q3 | 131.24 Thousand AUD | 0.0% |
| 2002 Q4 | 128.4 Thousand AUD | -2.17% |
| 2001 Q4 | 131.24 Thousand AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AdAlta Limited | 6.76 Million AUD | -383.004% |
| Acrux Limited | 8.55 Million AUD | -282.421% |
| Race Oncology Limited | 14.77 Million AUD | -121.367% |
| Biome Australia Limited | 7.91 Million AUD | -313.299% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -5333.02% |
| BTC Health Limited | -1.03 Million AUD | 3247.189% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -65.409% |
| CSL Limited | 7.56 Billion AUD | 99.568% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 41.931% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | -4.473% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 17.378% |
| Hexima Limited | 1 Million AUD | -3141.338% |
| Immutep Limited | 42.87 Million AUD | 23.739% |
| Memphasys Limited | 3.67 Million AUD | -788.896% |
| Noxopharm Limited | 7 Million AUD | -367.087% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -200.006% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -10827.119% |
| Starpharma Holdings Limited | 22.81 Million AUD | -43.307% |
| Tissue Repair Ltd | 6.66 Million AUD | -390.444% |
| Biotron Limited | 5.11 Million AUD | -539.779% |
| Alterity Therapeutics Limited | 23.4 Million AUD | -39.691% |
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -4503.804% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -1084.239% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -449.667% |
| Patrys Limited | 4.93 Million AUD | -562.78% |
| Orthocell Limited | 15.36 Million AUD | -112.739% |
| Imugene Limited | 135.09 Million AUD | 75.796% |
| PYC Therapeutics Limited | 60.91 Million AUD | 46.325% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -3564.995% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -193.944% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -203.163% |
| Nanollose Limited | 12.5 Thousand AUD | -261455.076% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -877.231% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -1563.782% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -287.602% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -692.586% |
| Nyrada Inc. | 4.55 Million AUD | -617.8% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 87.857% |
| Dimerix Limited | 25.64 Million AUD | -27.507% |
| PharmAust Limited | 6.65 Million AUD | -391.168% |
| AnteoTech Limited | 12.18 Million AUD | -168.294% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 49.777% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -50.785% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -619.344% |
| Actinogen Medical Limited | 22.77 Million AUD | -43.594% |
| Immuron Limited | 9.13 Million AUD | -257.817% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -295.41% |